Literature DB >> 12844488

Association of the DNA repair gene XPD Asp312Asn polymorphism with p53 gene mutations in tobacco-related non-small cell lung cancer.

Wei-Min Gao1, Marjorie Romkes, Richard D Day, Jill M Siegfried, James D Luketich, Hussam H Mady, Mona F Melhem, Phouthone Keohavong.   

Abstract

Lung cancer, a disease related mostly to tobacco smoke exposure and a leading cause of cancer-related death in industrialized countries, is frequently associated with mutations in the p53 tumor suppressor gene. Genetic differences resulting in inter-individual variation in DNA repair capacity may in part account for susceptibility of a cell to genotoxic agents leading to somatic mutations, including p53 mutations, and eventual transformation of a normal cell into a malignant phenotype. The objective of this study is to investigate the relationship between the polymorphisms of two DNA repair genes, the nucleotide excision repair xeroderma pigmentosum group D (XPD) gene (codons 312 and 751) and the base excision repair X-ray repair cross-complementing group 1 (XRCC1) gene (codon 399), and p53 mutations among lung cancer patients. Lung tumors from 204 smokers with non-small cell lung cancer (NSCLC) were analyzed for mutations in exons 5-8 of the p53 gene and genotypes of XPD and XRCC1. p53 mutations were found in 20% (40/204) of the patients. Patients with the XPD codon 312 Asn allele were less likely to have p53 mutations (13.8%) than XPD 312 Asp/Asp (27.3%) [odds ratio (OR) 0.43, 95% confidence interval (CI) 0.20-0.89, P = 0.023]. No association was found between p53 mutations and either XPD Lys751Gln or XRCC1 Arg399Gln. However, the p53 mutation frequency increased with the increased number of the combined genotypes among XPD 312WT (Asp/Asp), XPD 751VT (Lys/Gln or Gln/Gln) or XRCC1 399VT (Arg/Gln or Gln/Gln) (P = 0.01, trend test). These results suggest that individuals who smoke and have the XPD codon 312 Asp/Asp genotype may be at a greater risk of p53 mutations, especially if combined with other polymorphisms that may result in deficient DNA repair.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12844488     DOI: 10.1093/carcin/bgg115

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  9 in total

1.  The XPD Asp312Asn and Lys751Gln polymorphisms, corresponding haplotype, and pancreatic cancer risk.

Authors:  Li Jiao; Manal M Hassan; Melissa L Bondy; James L Abbruzzese; Douglas B Evans; Donghui Li
Journal:  Cancer Lett       Date:  2006-02-03       Impact factor: 8.679

2.  XRCC1 polymorphisms and lung cancer risk in Caucasian populations: a meta-analysis.

Authors:  Liangdong Chen; Deqiang Zhuo; Jiakuan Chen; Hongyin Yuan
Journal:  Int J Clin Exp Med       Date:  2015-09-15

3.  Genetic polymorphisms in the DNA repair genes XPD and XRCC1, p53 gene mutations and bladder cancer risk.

Authors:  Weimin Gao; Marjorie Romkes; Shilong Zhong; Tomoko Nukui; Raj A Persad; Patrick J B Smith; Robert Branch; Phouthone Keohavong
Journal:  Oncol Rep       Date:  2010-07       Impact factor: 3.906

4.  GSTT1 null genotype contributes to lung cancer risk in asian populations: a meta-analysis of 23 studies.

Authors:  Xin Yang; Man-Tang Qiu; Jing-Wen Hu; Xiao-Xiao Wang; Feng Jiang; Rong Yin; Lin Xu
Journal:  PLoS One       Date:  2013-04-24       Impact factor: 3.240

5.  Polymorphisms in apoptosis-related genes and TP53 mutations in non-small cell lung cancer.

Authors:  Eun Young Bae; Eun Jin Lee; Hyo-Gyoung Kang; Shin Yup Lee; Gwang Jin; Won Kee Lee; Jin Eun Choi; Hyo-Sung Jeon; Jeong Ok Lim; Eung Bae Lee; Jae Yong Park
Journal:  J Korean Med Sci       Date:  2011-10-27       Impact factor: 2.153

6.  Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients.

Authors:  Wenting Wu; Huan Li; Huibo Wang; Xueying Zhao; Zhiqiang Gao; Rong Qiao; Wei Zhang; Ji Qian; Jiucun Wang; Hongyan Chen; Qingyi Wei; Baohui Han; Daru Lu
Journal:  PLoS One       Date:  2012-03-29       Impact factor: 3.240

7.  What's your poison? Impact of individual repair capacity on the outcomes of genotoxic therapies in cancer. Part II - information content and validity of biomarkers for individual repair capacity in the assessment of outcomes of anticancer therapy.

Authors:  Rumena Petkova; Pavlina Chelenkova; Elena Georgieva; Stoian Chakarov
Journal:  Biotechnol Biotechnol Equip       Date:  2014-01-02       Impact factor: 1.632

8.  A comprehensive meta-analysis and a case-control study give insights into genetic susceptibility of lung cancer and subgroups.

Authors:  Debmalya Sengupta; Souradeep Banerjee; Pramiti Mukhopadhyay; Ritabrata Mitra; Tamohan Chaudhuri; Abhijit Sarkar; Gautam Bhattacharjee; Somsubhra Nath; Susanta Roychoudhury; Samsiddhi Bhattacharjee; Mainak Sengupta
Journal:  Sci Rep       Date:  2021-07-16       Impact factor: 4.379

9.  ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy.

Authors:  Maja Guberina; Ali Sak; Christoph Pöttgen; Ingeborg Tinhofer-Keilholz; Volker Budach; Panagiotis Balermpas; Jens Von der Grün; Claus Michael Rödel; Eleni Gkika; Anca-Ligia Grosu; Amir Abdollahi; Jürgen Debus; Claus Belka; Steffi Pigorsch; Stephani E Combs; David Mönnich; Daniel Zips; Chiara De-Colle; Stefan Welz; Annett Linge; Fabian Lohaus; Gustavo Baretton; Thomas Gauler; Michael Baumann; Mechthild Krause; Martin Schuler; Agnes Bankfalvi; Benedikt Höing; Stephan Lang; Martin Stuschke
Journal:  Pharmacogenomics J       Date:  2020-06-16       Impact factor: 3.550

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.